|
|
Volumn 25, Issue 12, 2007, Pages 1395-1402
|
|
Antivirals become a broader enterprise
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALBUMIN ALPHA INTERFERON;
ALPHA INTERFERON;
ANTIVIRUS AGENT;
ATAZANAVIR;
BEVIRIMAT;
BOCEPREVIR;
CPG 10101;
DNA VACCINE;
ENFUVIRTIDE;
HEPATITIS VACCINE;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
IMATINIB;
IMO 2125;
ISENTRESS;
MIFEPRISTONE;
NITAZOXANIDE;
PALIVIZUMAB;
PEGINTERFERON;
RALTEGRAVIR;
RIBAVIRIN;
TELAPREVIR;
THYMOSIN ALPHA1;
TNX 355;
UNCLASSIFIED DRUG;
VX 950;
WART VIRUS VACCINE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
CLINICAL TRIAL;
DRUG HALF LIFE;
DRUG TOLERABILITY;
EPIDEMIC;
HEPATITIS;
HEPATITIS C VIRUS;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNE RESPONSE;
LIVER CANCER;
LIVER CIRRHOSIS;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
WORLD HEALTH ORGANIZATION;
ANTIVIRAL AGENTS;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
INVESTMENTS;
UNITED STATES;
VIRUS DISEASES;
|
|
EID: 36849065284
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1207-1395 Document Type: Review |
|
Times cited : (24)
|
|
References (0)
|